Generic Name and Formulations:
Trivalent, inactivated, "subunit" influenza vaccine (virus types A and B); contains a total of 45mcg of hemagglutinin per 0.5mL dose; formulation changes annually; susp for IM inj; antibiotic- or preservative-free.
Indications for FLUCELVAX:
Adults and Children:
<4yrs: not established. Each dose is 0.5mL by IM inj once in the deltoid. 4–8yrs: 1 or 2 doses at least 1 month apart (depending on vaccination history as per annual ACIP recommendation). ≥9yrs: 1 dose.
Use current formulation only. Have appropriate medical treatment and supervision readily available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Latex allergy. Pregnancy (Cat.B). Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Local reactions (eg, pain, erythema), headache, fatigue, myalgia, malaise; syncope.
Single-dose prefilled Luer Lock syringe (0.5mL)—10 (without needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy